Coronary Heart Disease
Coronary Heart Disease
Coronary Heart Disease
DISEASE
Pembimbing
C
STABLE discomfort.
• Angina last 2 to 5 min and can radiate to
• Cardiac Enzymes
• CK-MB
• Troponin T, I
Emergency Department
• Goals for the management: control of cardiac discomfort, rapid identification of
patients who are candidates for urgent reperfusion therapy, triage of lower-risk patients
to the appropriate location in the hospital.
• Aspirin is essential in the management of patients with suspected STEMI and is effective
across the entire spectrum of acute coronary syndromes.
• Sublingual nitro-glycerine can be given safely to most patients with STEMI. Up to three
doses of 0.4 mg should be administered at about 5-min intervals. Nitro-glycerine may
be capable of both decreasing myocardial oxygen demand and increasing
myocardial oxygen supply.
• The primary tool for screening patients and making triage decisions is the initial 12-lead
ECG. When ST-segment elevation of at least 2 mm in two contiguous precordial leads
and 1 mm in two adjacent limb leads is present, a patient should be considered a
candidate for reperfusion therapy.
Hospital Phase Management
• Coronary care unit
• Continuous monitoring of cardiac rhythm, hemodynamic monitoring
• Patients should be admitted to a coronary care unit duration of stay is dictated by the
ongoing need for intensive care
• Activity
• Patients should be kept at bed rest for the first 6-12 hours
• Absence of complication: upright position by dangling by dangling their feet over the side of
the bed and sitting in a chair within the first 24 h.
• Psychologically beneficial and usually results in a reduction in the pulmonary capillary wedge
pressure.
Pharmacotherapy
• Antithrombotic agents
• primary goal :to maintain patency of the infarct-related artery, in conjunction with reperfusion
strategies.
• secondary goal: to reduce the patient’s tendency to thrombosis
• Beta – adrenoreceptor blocker
• Acute intravenous beta blockade improves the myocardial O2 supply-demand relationship,
decreases pain, reduces infarct size, and decreases the incidence of serious ventricular
arrhythmias.
• Inhibition of Renin - Angiotensin – Aldosterone system
• The mechanism involves a reduction in ventricular remodelling after infarction with a
subsequent reduction in the risk of CHF.